Rethinking Obesity: From Cost Burden to Investment Opportunity

How much should we spend to treat obesity? How much should the plan pay? How much should the member pay? These questions cannot be answered in a vacuum of disease-specific claims or obesity-specific utilization management. Obesity impacts the whole person and contributes to suffering across multiple clinical categories—rising healthcare costs are a symptom, not the root issue. True financial value comes from holistic, long-term claims analysis that captures the ripple effects of PROACTIVE CARE. For instance, avoiding a $12,000/month psoriasis drug with a $1,300/month obesity drug may not only drive significant cost savings and ROI, but also improve overall health outcomes. A recent study reinforces this idea, showing a strong association between central adiposity and increased psoriasis risk, especially among women (Ramessur et al., 2025). If we begin viewing each individual struggling with obesity as an investment—rather than a cost—we can reshape our entire care paradigm and justify allocating more resources upfront for greater long-term return. We begin to better understand the value of PROACTIVE CARE.

Ramessur, R., Saklatvala, J., Løset, M., Thomas, L. F., Budu-Aggrey, A., Mahil, S. K., Barker, J. N., Dand, N., Simpson, M. A., & Smith, C. H. (2025). Investigating the genetic basis of the influence of adiposity on psoriasis: A cross-sectional study in a large United Kingdom population–based biobank. Journal of Investigative Dermatology. Advance online publication. https://doi.org/10.1016/j.jid.2025.03.024